Objective: To determine a predictive factor for the risk of conversion from ocular myasthenia gravis (OMG) to generalized MG (GMG) in a prospective study.
Methods: RNA was isolated from serum samples and detection of microRNA (miRNA) expression analyzed with qPCR. In the discovery set, 179 human miRNAs were assayed for profiling of five OMG patients and four age- and gender-matched healthy controls. Based on the specific accumulation pattern of 19 miRNAs from the discovery set, in addition to miRNAs previously found elevated in generalized MG (GMG; miR-150-5p and miR-30e-5p), 21 miRNAs were subsequently analyzed in a validation cohort of 83 OMG patients (82 immunosuppression treatment naive; 49 male) within 3 months of diagnosis and at a follow-up visit (median duration 28 months from first visit).
Results: Thirteen patients generalized 14.8 ± 12.0 months after the diagnosis and the majority (85%) belonged to the late onset MG group. Two miRNAs were significantly higher in secondary GMG (SGMG) patients compared to OMG patients with late onset MG: miR-30e-5p (9.1 ± 0.5 vs. 6.3 ± 0.9; < 0.0001) and miR-150-5p (7.4 ± 1.1 vs. 6.4 ± 1.1; = 0.01). The sensitivity for miR-30e-5p in differentiating OMG and SGMG was 96% in all OMG patients and 100% in late onset OMG patients.
Interpretation: This is the first study to describe a potential predictive factor associated with the risk of generalization for patients with OMG. Raised levels (>8) of miR-30e-5p at initial presentation in patients with ocular MG symptoms, give a predictive cut-off for subsequent generalization of 96-100%.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389736 | PMC |
| http://dx.doi.org/10.1002/acn3.692 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study.
Ther Adv Neurol Disord
January 2025
Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Background: China has a large number of myasthenia gravis (MG) patients, creating an urgent need for rapid and tolerable treatment options. As the first-approved Fc receptor antagonist, efgartigimod has bright prospects for treating MG. However, real-world evidence on its application within the Chinese MG population are limited.
View Article and Find Full Text PDFMulti-Institutional Analysis of Surgery for Lichen Sclerosus Induced Penile Urethral Stricture: Establishing Single-Stage Urethroplasty as a Primary Treatment Option.
J Urol
January 2025
Division of Urology, Department of Surgery, University of Alberta, Edmonton, Alberta.
Introduction: Ideal treatment of lichen sclerosus (LS) induced penile urethral strictures (PUS) remains elusive. The objective of this study is to compare multi-institutional outcomes of single-stage urethroplasty (SSU) with oral mucosal graft (OMG), staged urethroplasty and perineal urethrostomy (PU) for treatment of LS induced PUS.
Methods: Multi-institutional analysis was performed at 9 centers on males undergoing SSU, staged urethroplasty or PU for LS induced PUS.
[Successful treatment of rheumatoid arthritis complicated with myasthenia gravis with low-dose rituximab: A case report].
Beijing Da Xue Xue Bao Yi Xue Ban
December 2024
Department of Rheumatology and Immunology, Peking University Shougang Hospital, Beijing 100144, China.
Rheumatoid arthritis (RA) and myasthenia gravis (MG) are two distinct autoimmune diseases. Compared with the general population, the incidence of RA is notably higher among patients with MG. Similarly, the rate of MG in patients diagnosed with RA is also significantly increased.
View Article and Find Full Text PDFMulticenter Validation of the Ocular Myasthenia Gravis Rating Scale Questionnaire.
Neurology
January 2025
From the Department of Neuro-Ophthalmology (S.H.W.), Moorfields Eye Hospital NHS Foundation Trust; Departments of Ophthalmology and Neurology (S.H.W.), Guy's and St Thomas' NHS Foundation Trust; Department of Ophthalmology (S.H.W.), Faculty of Life Sciences & Medicine, King's College London; Department of Clinical and Movement Neuroscience (S.H.W.), UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Ophthalmology and Visual Sciences (R.A., W.T.C., T.D., J.R.E., C.A.A., L.B.D.L.), Kellogg Eye Center, University of Michigan, Ann Arbor; Departments of Ophthalmology, Neurology, and Neurosurgery (E.R.E., S.K.), Mayo Clinic, FL; Survey Research Center (J.R.E.), Institute for Social Research, University of Michigan, Ann Arbor; and Division of Neurology (C.B.-T.), Department of Medicine, University Health Network and University of Toronto, Ontario, Canada.
Background And Objectives: Ocular myasthenia gravis (OMG) causes disabling ocular symptoms of ptosis and diplopia, but a validated disease-specific patient-reported outcome measure (PROM) has not been reported. We sought to validate a novel PROM for OMG, OMG Rating Scale Questionnaire (OMGRate-q), as a measure of visual functioning to support patient-centered care.
Methods: This was a prospective study of patients aged 18 years and older with OMG receiving care at 3 medical centers (January 2022-October 2023).
Ocular Myasthenia gravis: determining the predictive factors of secondary generalisation.
Acta Neurol Belg
December 2024
Neurology unit, Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Introduction: Myasthenia gravis (MG) can be classified according to clinical features into ocular MG (OMG) and generalised MG (GMG). However, OMG carries the risk of conversion to GMG. In this study, we aimed to determine the predictive factors for the secondary generalisation of OMG patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!